# National Medical Products Administration

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/national-medical-products-administration
Canonical HTML page: https://gethealthbrief.com/entity/national-medical-products-administration

## Timeline

- **2026-03-24**: Phase III Initiation — First patient dosed at Peking Union Medical College Hospital in China.
- **2026-01-15**: Regulatory Designations — FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
- **2025-Q4**: Phase II Data Publication — Results showing efficacy without hormonal side effects published in The Lancet.

## Recent coverage (2 stories)

### 5,215 China Trials in 2025 Cost 60% Less Than US: Security Risks Loom
2026-06-24 10:39:39 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

China’s clinical drug trials hit a record 5,215 in 2025, with costs 50–60% lower than in the US. This surge, driven by Beijing’s biotech ambitions, is reshaping global drug development and raising national security concerns in Washington as Chinese firms gain dominance in cancer and vaccine research.
Full story: https://gethealthbrief.com/story/china-record-drug-trials-2025-cost-security

### Hope Medicine Doses First Phase III Patient for Non-Hormonal Endometriosis Drug
2026-03-25 12:12:33 · Sentiment: Positive · Impact: 7/10 · Sources: 10

Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Full story: https://gethealthbrief.com/story/hope-medicine-hmi115-phase-3-endometriosis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.